NCVR October Roll-out: Update

As confirmed previously, the ‘Enhanced’ Roll-out of the National Contract Value Review (NCVR) will be coming in October, ending the local negotiation of commercial research costings beyond the Lead Organisation for all later phase studies within the NHS.

The confirmed timeline will be as follows:

• 1st October will see the release of the revised financial appendix as part of unmodified model agreements. 

• From 17th October, changes within the interactive Costing Tool (iCT) functionality and some cost calculations will be released.

• An updated tariff, including the NHS Organisation specific multiplier, will apply to all commercial contract studies included in NCVR that have not yet signed contracts with participating sites by the end of October.

These changes will apply to all un-contracted commercial projects, including those currently in ongoing negotiations.

This excludes phase I-IIa, ATMP and studies in Primary Care studies, although NHS organisations are strongly encouraged to accept the outcome and iCT generated prices for these studies. WFC are continuing to work with the Experimental Cancer Medicine Centre (ECMC) Network to deliver an NCVR solution for early-phase and ATMP trials.

Further info concerning NCVR can be found on the NHSE updated webpage.